LONDON, July 31 (Reuters) – Scientists and drug companies
will continue to research the potential of alternative Ebola
vaccines, despite a shot from Merck and NewLink Genetics
proving 100 percent effective in a trial in Guinea.
Experts said on Friday different kinds of vaccines were
needed that might be better suited for different population
LONDON (Reuters) – AstraZeneca (AZN.L: Quote, Profile, Research, Stock Buzz) revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from selling rights to medicines offset generic competition to older drugs and a strong dollar.
The drugmaker increased its revenue forecast for the year and said it now expected a low single-digit percentage decline, against mid single-digit previously, while core earnings are still expected to increase at a low single-digit rate.
LONDON (Reuters) – Drugmaker GlaxoSmithKline, which was fined a record 3 billion yuan ($483 million) for corruption in China last year and is examining possible staff misconduct elsewhere, faces new allegations of bribery in Romania.
GSK confirmed it was looking into the latest claims of improper payments set out in a whistleblower’s email sent to its top management on Monday. A copy of the email was seen by Reuters.
LONDON (Reuters) – GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts.
Strong sales of Tivicay and Triumeq validated GSK’s decision in May to keep its HIV business, rather than spinning it off, and offset a further slide in revenue from lung drug Advair and lower group profit margins following a major business overhaul.
LONDON (Reuters) – A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) in the second quarter, although core earnings per share fell by a less than expected 9 percent.
The drugmaker recently sold its marketed cancer drugs to Novartis (NOVN.VX: Quote, Profile, Research, Stock Buzz) and bought the Swiss group’s vaccines, while increasing its consumer health business through a joint venture.
LONDON, July 27 (Reuters) – Two of the most anticipated new
heart drugs to be launched in recent years have been priced well
above analyst expectations, fuelling the debate about whether
modern medicines cost too much.
Praluent, made by Sanofi and Regeneron
Pharmaceuticals, and Entresto from Novartis
are both treatments that represent significant advances for
millions of patients at risk of serious heart problems.
LONDON (Reuters) – AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche’s blockbuster medicine Avastin.
Its new 50/50 joint venture with Fujifilm Kyowa Kirin Biologics (FKB) will work on a copycat version of Avastin, which is currently used in a range of solid tumors and also has potential to be given alongside new immunotherapy treatments.
LONDON, July 24 (Reuters) – A new type of cholesterol drug
from Sanofi and Regeneron Pharmaceuticals won
a green light from European regulators on Friday, two months
behind a rival product from Amgen.
The European Medicines Agency (EMA) said its experts had
recommended Praluent for patients unable to control their
cholesterol despite taking optimal doses of conventional statin
pills or who cannot take statins.
(Reuters) – Swiss biotech firm AC Immune is one step closer to a potential stock market listing after a decision this week by partner Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) to advance its experimental Alzheimer’s drug crenezumab into pivotal clinical tests.
“It’s very significant for us,” Chief Executive Andrea Pfeifer told Reuters. “It validates our pipeline, it validates our technology and it gives us very nice push in valuation.”
(Reuters) – Switzerland’s Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) expects no copycat competition to its biotech cancer drugs for another two years, giving it space to grow a successful portfolio of new and established medicines.
The strategy is working so far, with group sales in the first half increasing by a slightly better-than-expected 3 percent as demand for oncology drugs helped offset the strength of the Swiss franc.